Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock
Here's how this drugmaker proved the bears wrong, and why that means it's worth investing $1,500 in today. Read More: Earn up ...
News Medical1d
Argonne receives $21.7 million to advance cancer and vaccine discoveries
Argonne National Laboratory will use its world-leading capabilities in artificial intelligence (AI) and high performance computing to research novel ways to fight cancer and transform vaccine ...
Crain's Chicago Business1d
UChicago to harness Argonne's AI, supercomputer tools for cancer drug discovery
With a federal grant in hand, researchers at the health system and national lab will try to hit fast forward on the long and ...
The University of Chicago Chronicle1d
Argonne, UChicago partner to accelerate discovery of new cancer therapies using AI
The UChicago Medicine team will be led by Odunsi as co-principal investigator and includes Christopher Weber, Savas Tay, and ...
Positive Outlook on AbbVie: Geoff Meacham’s Buy Rating and Potential of Emraclidine Amid Schizophrenia Trial Challenges
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...
AbbVie Buy Rating Affirmed Despite Emraclidine Setback, Driven by Skyrizi and Rinvoq Growth
Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...